GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2306.25

(-1.23%)

Total Liabilities Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual total liabilities in 2023 was 17.96 Billion INR , up 13.3% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly total liabilities in 2024 Q2 was 20.73 Billion INR , up 216.63% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported annual total liabilities of 15.85 Billion INR in 2022, down -19.54% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported annual total liabilities of 19.7 Billion INR in 2021, up 20.41% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly total liabilities of 20.73 Billion INR for 2024 Q2, up 216.63% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly total liabilities of 17.96 Billion INR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Total Liabilities of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Total Liabilities	Total Liabilities Growth
2023	17.96 Billion INR	13.3%
2022	15.85 Billion INR	-19.54%
2021	19.7 Billion INR	20.41%
2020	16.36 Billion INR	24.45%
2019	13.14 Billion INR	-25.77%
2018	17.71 Billion INR	-6.28%
2017	18.9 Billion INR	89.59%
2016	9.96 Billion INR	14.38%
2015	8.71 Billion INR	11.7%
2014	7.8 Billion INR	-31.54%
2013	11.39 Billion INR	5.38%
2012	10.81 Billion INR	-1.14%
2011	10.94 Billion INR	27.37%
2010	8.58 Billion INR	20.68%
2009	7.11 Billion INR	-4.47%
2008	7.44 Billion INR	13.69%
2007	6.55 Billion INR	12.14%
2006	5.84 Billion INR	3.83%
2005	5.62 Billion INR	14.8%
2004	4.9 Billion INR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	-17.77 Billion INR	-198.97%
2024 Q2	20.73 Billion INR	216.63%
2023 Q4	17.96 Billion INR	0.0%
2023 Q1	- INR	-100.0%
2023 Q2	17.3 Billion INR	0.0%
2023 FY	17.96 Billion INR	13.3%
2023 Q3	- INR	-100.0%
2022 Q4	15.85 Billion INR	0.0%
2022 FY	15.85 Billion INR	-19.54%
2022 Q1	- INR	-100.0%
2022 Q2	15.6 Billion INR	0.0%
2022 Q3	- INR	-100.0%
2021 Q1	- INR	-100.0%
2021 FY	19.7 Billion INR	20.41%
2021 Q2	17.58 Billion INR	0.0%
2021 Q4	19.7 Billion INR	0.0%
2021 Q3	- INR	-100.0%
2020 Q3	- INR	-100.0%
2020 FY	16.36 Billion INR	24.45%
2020 Q4	16.36 Billion INR	0.0%
2020 Q2	14.1 Billion INR	0.0%
2020 Q1	- INR	-100.0%
2019 Q4	13.14 Billion INR	0.0%
2019 FY	13.14 Billion INR	-25.77%
2019 Q1	- INR	-100.0%
2019 Q2	11.73 Billion INR	0.0%
2019 Q3	- INR	-100.0%
2018 Q4	17.71 Billion INR	0.0%
2018 Q1	- INR	0.0%
2018 FY	17.71 Billion INR	-6.28%
2017 FY	18.9 Billion INR	89.59%
2016 FY	9.96 Billion INR	14.38%
2015 FY	8.71 Billion INR	11.7%
2014 FY	7.8 Billion INR	-31.54%
2013 FY	11.39 Billion INR	5.38%
2012 FY	10.81 Billion INR	-1.14%
2011 FY	10.94 Billion INR	27.37%
2010 FY	8.58 Billion INR	20.68%
2009 FY	7.11 Billion INR	-4.47%
2008 FY	7.44 Billion INR	13.69%
2007 FY	6.55 Billion INR	12.14%
2006 FY	5.84 Billion INR	3.83%
2005 FY	5.62 Billion INR	14.8%
2004 FY	4.9 Billion INR	0.0%

Peer Total Liabilities Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Total Liabilities	Total Liabilities Difference
Abbott India Limited	14.94 Billion INR	-20.174%
Cipla Limited	59.15 Billion INR	69.637%
Gland Pharma Limited	19.37 Billion INR	7.293%
Kopran Limited	2.52 Billion INR	-612.74%
Marksans Pharma Limited	5.95 Billion INR	-201.844%
NGL Fine-Chem Limited	929.03 Million INR	-1833.303%
Pfizer Limited	6.33 Billion INR	-183.639%
Sanofi India Limited	6.99 Billion INR	-156.734%
SMS Pharmaceuticals Limited	4.97 Billion INR	-260.837%